A major gap is emerging between circulating flu viruses and the vaccines designed to stop them. According to a comprehensive analysis of over 13,800 flu samples tested in Australia during 2025, only 43% of A(H3N2) viruses matched the World Health Organization's recommended vaccine strains for the Southern Hemisphere, compared to more than 99% for A(H1N1)pdm09 viruses and 98% for influenza B viruses. This mismatch raises concerns about how well current vaccines will protect against one of the most common flu strains circulating globally.

Why Is A(H3N2) Drifting Away From Vaccine Targets?

The Melbourne WHO Collaborating Centre for Reference and Research on Influenza, part of the global influenza surveillance network, analyzed samples from across Australia to understand how well circulating viruses align with vaccine formulations. The centre received 13,817 human influenza-positive samples during 2025, making this one of the most comprehensive snapshots of flu virus genetics available. Among these, A(H1N1)pdm09 viruses dominated, accounting for 46.1% of all samples, followed by A(H3N2) at 21.2% and influenza B at 19.5%.

The problem with A(H3N2) is that it evolves rapidly. Viruses naturally accumulate small genetic changes over time, and A(H3N2) is particularly prone to this drift. When a virus drifts too far from the vaccine strain, the immune system's antibodies, trained to recognize the vaccine version, may not work as effectively against the new variant. This doesn't mean the vaccine fails entirely, but it can reduce protection levels.

What Does This Mean for Flu Vaccine Effectiveness?

The 43% match rate for A(H3N2) is significantly lower than what public health officials typically aim for. When vaccine strains align closely with circulating viruses, protection rates tend to be higher. The stark contrast between A(H3N2) (43% match) and A(H1N1)pdm09 (over 99% match) suggests that people vaccinated against the flu in 2025 may have received stronger protection against H1N1 and B strains but potentially weaker protection against A(H3N2).

This finding underscores a long-standing challenge in flu prevention: the virus evolves faster than vaccine manufacturers can respond. The WHO recommends vaccine strains twice yearly, once for the Northern Hemisphere and once for the Southern Hemisphere, but by the time a vaccine reaches people's arms, the virus may have already shifted. Researchers at the Melbourne centre are tasked with monitoring these changes and alerting global health authorities when drift becomes significant enough to warrant vaccine strain updates.

How Are Researchers Tracking Flu Virus Changes?

The Melbourne WHO Collaborating Centre employs multiple strategies to understand flu virus evolution and predict which strains will dominate in coming seasons. These monitoring approaches include:

• Antigenic Analysis: Scientists test whether antibodies from vaccinated people can recognize and neutralize circulating viruses, directly measuring how well vaccine protection holds up against real-world strains.
• Genetic Sequencing: Researchers decode the DNA of flu viruses to identify mutations and track which genetic variants are spreading, allowing them to spot drift before it becomes widespread.
• Antiviral Susceptibility Testing: The centre checks whether circulating viruses remain sensitive to antiviral medications like oseltamivir (Tamiflu) and zanamivir, ensuring treatment options remain effective.

In 2025, the centre tested 3,307 samples for susceptibility to neuraminidase inhibitors, the main class of antiviral drugs used to treat flu. The results were reassuring: only 37 A(H1N1)pdm09 viruses showed highly reduced inhibition by oseltamivir, and no influenza viruses tested showed resistance to zanamivir. This means antivirals remain a viable backup treatment option, even if vaccine protection varies.

What About Newer Antiviral Drugs?

Beyond traditional antivirals, researchers also screened for resistance to baloxavir marboxil, a newer antiviral that works through a different mechanism. Of 5,080 samples with genetic sequencing data, none carried genetic markers associated with reduced susceptibility to baloxavir marboxil. This is positive news for patients who might need treatment with this newer drug, though it remains less widely used than oseltamivir.

The data suggests that while vaccine strain matching is a concern, the antiviral arsenal remains intact. However, antivirals are typically reserved for people at high risk of severe illness, such as older adults, pregnant women, and those with chronic health conditions. For the general population, vaccination remains the primary defense against flu.

What Should People Know About Flu Prevention Going Forward?

The findings from the Melbourne centre highlight why flu vaccination remains important, even when vaccine strains don't perfectly match circulating viruses. A vaccine that is only 43% matched to circulating A(H3N2) strains still provides meaningful protection, reducing the risk of severe illness and hospitalization. Partial protection is far better than no protection.

Public health authorities use data like this to inform vaccine strain recommendations for the following year. The WHO's Global Influenza Surveillance and Response System (GISRS), which includes the Melbourne centre, continuously monitors virus evolution worldwide and recommends vaccine updates when drift becomes significant. This is why flu vaccines change annually, unlike some other vaccines that remain stable for years.

For individuals, the takeaway is straightforward: get vaccinated each flu season, even if you received a flu shot the previous year. The virus changes, and so does the vaccine. People at higher risk of severe flu complications should also discuss antiviral medications with their healthcare provider, as these drugs can reduce illness duration and severity if taken early after symptoms begin.